Optimising endocrine therapy for oestrogen receptor-positive metastatic breast cancer
Clinical trials with abemaciclib in advanced breast cancer patients have shown significant improved outcomes with rapid tumour growth, endocrine resistance and visceral disease
You will learn:
• To understand the cell signalling pathways involved in breast cancer
• To understand the role of CDK4/6 inhibitors in the management of advanced breast cancer
• To understand differences between the currently available CDK4/6 inhibitors
• To identify which patients with advanced breast cancer might be suitable for treatment with abemaciclib.
To access this module, please register or login: